In yesterday’s Wall Street session, TG Therapeutics Inc. (NASDAQ:TGTX) shares traded at $11.29, up 2.17% from the previous session.
9 analysts cover TG Therapeutics Inc. (NASDAQ:TGTX), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $41.00 and a low of $6.00, we find $32.00. Given the previous closing price of $11.05, this indicates a potential upside of 189.59 percent. TGTX stock price is now -30.32% away from the 50-day moving average and -35.72% away from the 200-day moving average. The market capitalization of the company currently stands at $1.68B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 7. Brokers who have rated the stock have averaged $28.94 as their price target over the next twelve months.
With the price target reduced from $16 to $12, Goldman Upgraded its rating from Sell to Neutral for TG Therapeutics Inc. (NASDAQ: TGTX).
In other news, WEISS MICHAEL S, CEO and President bought 100,000 shares of the company’s stock on Aug 11. The stock was bought for $1,013,000 at an average price of $10.13. Upon completion of the transaction, the CEO and President now directly owns 12,073,021 shares in the company, valued at $136.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23, Director Lonial Sagar sold 34,854 shares of the business’s stock. A total of $814,538 was realized by selling the stock at an average price of $23.37. This leaves the insider owning 93,878 shares of the company worth $1.06 million. Insiders disposed of 138,501 shares of company stock worth roughly $1.56 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TGTX stock. A new stake in TG Therapeutics Inc. shares was purchased by HOLOCENE ADVISORS, LP during the first quarter worth $18,353,000. RENAISSANCE TECHNOLOGIES LLC invested $6,054,000 in shares of TGTX during the first quarter. In the first quarter, CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in TG Therapeutics Inc. valued at approximately $3,699,000. CLEAR STREET LLC acquired a new stake in TGTX for approximately $3,614,000. OSSIAM purchased a new stake in TGTX valued at around $3,153,000 in the second quarter.
On Thursday morning TG Therapeutics Inc. (NASDAQ: TGTX) stock kicked off with the opening price of $10.92. During the past 12 months, TG Therapeutics Inc. has had a low of $4.86 and a high of $35.67. As of last week, the company has a debt-to-equity ratio of 2.41, a current ratio of 2.90, and a quick ratio of 2.50. The fifty day moving average price for TGTX is $15.97 and a two-hundred day moving average price translates $17.58 for the stock.
The latest earnings results from TG Therapeutics Inc. (NASDAQ: TGTX) was released for Jun, 2023. The company reported revenue of $16.07 million for the quarter, compared to $0.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2606.06 percent.
TG Therapeutics Inc.(TGTX) Company Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
